×
+ All Categories
Log in
English
Français
Español
Deutsch
Report -
Q3/FY2016 FINANCIALRESULTS - Astellas Pharma · Q3/FY15 Q3/FY16 2,865 2,889 (+0.8%) Q3/FY15 Q3/FY16 68.8 XTANDI and OAB products growth CRESEMBA contribution XTANDI growth Prografand
Name
Email
Select
Select
Pornographic
Defamatory
Illegal/Unlawful
Spam
Other Terms Of Service Violation
File a copyright complaint
Message
Please pass captcha verification before submit form